Kazia Therapeutics Limited (KZIA) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low4.4·High4.4
P/B Ratio
↓
N/A
—
5yr avg: 2.63
30Y Low0.3·High17.2
ROE
↓
N/A
—
5yr avg: -722.7%
30Y Low-274%·High27%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KZIA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kazia Therapeutics Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $16M | $7M | $5M | $21M | $56M | $116M | $26M | $78M | $15M | $18M | $33M |
| Enterprise Value | $13M | $3M | $4M | $18M | $50M | $88M | $17M | $73M | $9M | $3M | $-81078 |
| P/E Ratio → | -1.08 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 530.20 | 163.52 | 2.38 | 38520.36 | 5565.00 | 7.64 | 26.15 | 49939.02 | 1139.91 | 2.00 | 8.20 |
| P/B Ratio | — | — | — | 1.77 | 3.05 | 3.07 | 1.83 | 5.51 | 0.78 | 0.69 | 0.98 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KZIA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 69.50 | 1.94 | 32313.15 | 5013.00 | 5.83 | 17.28 | 46466.81 | 691.94 | 0.36 | -0.02 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
KZIA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Kazia Therapeutics Limited earns an operating margin of -33850.0%. Operating margins have expanded from -4346661.1% to -33850.0% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -33850.0% | -33850.0% | -1233.2% | -4346661.1% | -253990.0% | -42.0% | -1234.3% | -535463.3% | -95262.4% | -123.5% | -313.7% |
| Net Profit Margin | -49290.5% | -49290.5% | -1160.2% | -3687419.8% | -250140.0% | -55.5% | -1261.7% | -656230.0% | -46071.1% | -121.4% | -296.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -2634.3% | -135.0% | -89.1% | -32.4% | -88.0% | -61.4% | -27.1% | -36.0% | -30.8% |
| ROA | -149.8% | -149.8% | -107.8% | -64.0% | -53.2% | -20.8% | -56.4% | -41.6% | -18.8% | -29.9% | -29.5% |
| ROIC | — | — | — | -169.4% | -165.5% | -61.2% | -129.5% | -56.8% | -77.2% | -143.0% | -4002.9% |
| ROCE | — | — | -349.1% | -97.1% | -64.4% | -18.8% | -66.0% | -38.7% | -45.6% | -33.6% | -32.6% |
KZIA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $4M exceeds total debt of $396000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.15 | 0.10 | — | — | — | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -0.29 | -0.30 | -0.73 | -0.62 | -0.38 | -0.31 | -0.57 | -0.99 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -12129.42 | — | — | -3.83 | — | — | — |
Net cash position: cash ($4M) exceeds total debt ($396000)
KZIA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.35x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 1.42x to 0.35x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.35 | 0.35 | 0.24 | 1.42 | 1.40 | 3.53 | 2.10 | 3.42 | 2.38 | 3.62 | 23.81 |
| Quick Ratio | 0.35 | 0.35 | 0.24 | 1.42 | 1.40 | 3.53 | 2.10 | 3.42 | 2.38 | 3.62 | 23.50 |
| Cash Ratio | 0.31 | 0.31 | 0.06 | 0.69 | 1.09 | 3.31 | 1.73 | 2.46 | 1.53 | 2.68 | 23.36 |
| Asset Turnover | — | 0.01 | 0.11 | 0.00 | 0.00 | 0.26 | 0.04 | 0.00 | 0.00 | 0.24 | 0.11 |
| Inventory Turnover | 1.42 | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 782.14 | 21.03 | 69054.05 | 1861.50 | — | 0.16 | 363270.79 | 31.47 | 0.21 | 8.16 |
KZIA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kazia Therapeutics Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $479600 | $368600 | $265000 | $235400 | $152459 | $120007 | $100959 | $97634 | $89203 |
Peer Comparison
Compare KZIA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KZIAYou | $16M | -1.1 | — | — | 100.0% | -33850.0% | — | — | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 SNDX | $2B | -5.5 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 AGIO | $2B | -4.1 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 TGTX | $8B | 17.9 | 62.8 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 PRTA | $432M | -1.8 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 IDYA | $3B | -22.6 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 AGEN | $137M | -970.6 | — | — | 29.6% | -18.0% | — | — | — |
 ALDX | $106M | -3.1 | — | — | — | — | -58.7% | -245.8% | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
What if you invested $1,000 in KZIA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in KZIA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KZIA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKZIA vs NKTR — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Nektar Therapeutics.
Compare NowKZIA — Frequently Asked Questions
Quick answers to the most common questions about buying KZIA stock.
What is Kazia Therapeutics Limited's P/E ratio?
Kazia Therapeutics Limited's current P/E ratio is -1.1x. The historical average is 2.1x.
Is KZIA stock overvalued?
Based on historical data, Kazia Therapeutics Limited is trading at a P/E of -1.1x. Compare with industry peers and growth rates for a complete picture.
What are Kazia Therapeutics Limited's profit margins?
Kazia Therapeutics Limited has 100.0% gross margin and -33850.0% operating margin.